

Allergy Immunotherapy Market to Exceed \$4.9B: 20-Country Study (2024-2033)

PORTLAND, OR, UNITED STATES,
November 19, 2024 /

EINPresswire.com/ -- The global [allergy immunotherapy market](#), valued at \$1.8 billion in 2023, is projected to reach \$4.9 billion by 2033, with a robust CAGR of 10.4% from 2024 to 2033. This growth is driven by the rising prevalence of allergic disorders and advancements in immunotherapy techniques, alongside increasing awareness and adoption of long-term allergy treatments.

Report Insights



Market was valued at
\$1.8 Billion
2023




Projected to reach
\$4.9 Billion
2033



Growing at a CAGR
10.4% From
2024-2033

CAGR 10.4%



Allergy Immunotherapy Market
Report Code: AI0241

Allied Market Research
© All right reserved

Allergy Immunotherapy Market

□□□ □ □□□□□□ □□□□ □□ □□□□ □□□□□□: <https://www.alliedmarketresearch.com/request-sample/A10241>

Market Overview

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment designed to reduce sensitivity to allergens. Through gradual exposure to allergens, either via injections (subcutaneous immunotherapy) or sublingual tablets/drops (sublingual immunotherapy), the immune system becomes less reactive over time, reducing the severity of allergic reactions. This treatment is especially effective for conditions like allergic rhinitis, asthma, and insect venom allergies.

Key Takeaways

- The market study covers 20 countries, providing segment analysis by value (\$Billion) for 2024-2033.
- Extensive research involved reviewing over 1,500 documents, including industry reports, authentic journals, and government releases.
- Data integration offers balanced insights, supporting stakeholders in making informed decisions.

Market Dynamics

Drivers

- **Increasing Allergy Prevalence:** The World Health Organization predicts that by 2050, half the global population will suffer from allergic diseases.
- **Advancements in Therapy:** Innovations such as sublingual immunotherapy (SLIT) and personalized treatment options are making therapies safer and more accessible.

Restraints

- **High Costs:** Allergy immunotherapy treatments remain expensive, with costs compounded by the long duration of treatment and frequent healthcare visits.
- **Adherence Challenges:** The prolonged nature of therapy often leads to patient dropout, diminishing overall effectiveness.

Opportunities

- **Digital Health Integration:** Telemedicine and remote monitoring can improve adherence and expand access in underserved regions.
- **Next-Generation Therapies:** Ongoing research into novel allergens and innovative delivery methods, such as oral or intranasal immunotherapy, holds promise for tailored treatments.
- **Rising Awareness:** Educational campaigns are increasing acceptance among patients and healthcare providers.

Gender Disparities in Allergies

A 2022 study highlights gender differences in self-reported allergies:

- Women report higher prevalence of allergies compared to men, including pollen (10.4% vs. 6.2%), food (6.8% vs. 3.0%), and drug allergies (7.6% vs. 3.0%).
- These disparities influence the demand for allergy immunotherapy, underscoring the need for gender-specific insights in market strategies.

Market Segmentation

By Type:

- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)

By Application:

- Allergic Rhinitis
- Asthma
- Food Allergies
- Others

By Distribution Channel:

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

By Region:

- North America

- Europe
- Asia-Pacific
- LAMEA

Regional Insights

- North America: Dominates due to high allergy prevalence and advanced healthcare infrastructure.
- Europe: Supported by favorable reimbursement policies and extensive research.
- Asia-Pacific: Rapid growth driven by rising allergy awareness and healthcare access in countries like China and Japan.
- Emerging Markets: Latin America and the Middle East show potential due to increased investments and rising allergy rates.

Industry Trends

- In September 2023, Stallergenes Greer partnered with Nestlé for peanut allergy oral immunotherapy.
- In February 2024, the FDA approved Xolair for immunoglobulin E-mediated food allergies.

Competitive Landscape

Key players include:

- Torii Pharmaceutical Co., Ltd.
- Biomay AG
- ALK-Abello A/S
- HAL Allergy Group
- Stallergenes Greer
- Leti Pharma

Recent Developments

- In April 2021, ALK-Abelló A/S initiated clinical trials for sublingual immunotherapy tablets for birch pollen-induced allergic rhinitis.
- In October 2022, Allergy Partners collaborated with Aimmune Therapeutics for peanut allergy treatment.

Conclusion

The allergy immunotherapy market presents significant growth opportunities, fueled by technological advancements, rising awareness, and increasing allergy prevalence. Addressing cost barriers and enhancing accessibility through digital innovations will be critical for market expansion.

Benefits for Stakeholders

- Comprehensive analysis of market trends and opportunities.
- Insights into regional variations and key drivers.

- Strategic guidance for informed decision-making and growth planning.

For more information, please contact: <https://www.alliedmarketresearch.com/purchase-enquiry/A10241>

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/761854615>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.